Literature DB >> 2187784

Is it possible to predict the activity of a new antidepressant in animals with simple psychopharmacological tests?

M Bourin1.   

Abstract

Behavioural tests for predicting antidepressant activity in the animal provide a closer approximation than other tests of states of depression in man but are often long and costly to perform (except the behavioural despair test). The tests proposed here presuppose a pharmacological interaction (except the Porsolt test) but are simple enough to allow screening: included are antagonism of reserpine hypothermia, ptosis and akinesia; antagonism of effects induced by oxotremorine; antagonism of high-dose apomorphine; and potentiation of yohimbine toxicity. In combination with the study of motor activity in the mouse, these tests allow assessment of the specificity of antidepressant activity by establishing a ratio between the "antidepressant" dose and the "stimulant" or "sedative" dose. It can be predicted that a substance will be antidepressant and sedative or stimulant at the same dose if the ratio is close to 1; if the ratio is less than 1, at antidepressant doses the substance will be very sedative or stimulant according to the case. The specificity of the tests discussed can be debatable. Antagonism of reserpine-induced hypothermia indicates substances with direct or indirect beta-mimetic activity, ptosis antagonism, substances with alpha-adrenergic (not antidepressants) or serotoninergic (possibly antidepressants) activity; and akinesia antagonism, a direct or indirect dopaminergic activity (sometimes found in antidepressants) with psychostimulant activity. The oxotremorine test is related to the anticholinergic activity of substances, except in the case of hypothermia antagonism. The high-dose apomorphine test seems to be specific for substances inhibiting norepinephrine reuptake. The yohimbine test is simple to carry out, relatively inexpensive and does not fail to screen any molecule known to be effective to-date. The behavioural despair test is a good complement for screening except for drugs having a beta-agonist activity, it appears that this test is dependent on functional relationships between alpha 2 and serotonergic systems.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2187784     DOI: 10.1111/j.1472-8206.1990.tb01016.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  8 in total

Review 1.  Forced swimming test in mice: a review of antidepressant activity.

Authors:  Benoit Petit-Demouliere; Franck Chenu; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

2.  Effects of sibutramine on the central dopaminergic system in rodents.

Authors:  T Nakagawa; K Ukai; T Ohyama; Y Gomita; H Okamura
Journal:  Neurotox Res       Date:  2001-07       Impact factor: 3.911

Review 3.  Genetic variation in cortico-amygdala serotonin function and risk for stress-related disease.

Authors:  Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2008-03-26       Impact factor: 8.989

4.  Neonatal Reserpine Administration Produces Widespread Neuronal Losses and ⍺-Synuclein Inclusions in a Rat Model.

Authors:  Rianita van Onselen; Tim G Downing
Journal:  Neurotox Res       Date:  2021-11-02       Impact factor: 3.911

5.  Antidepressant-like effects of methanol extract of Hibiscus tiliaceus flowers in mice.

Authors:  Cláudia Vanzella; Paula Bianchetti; Sabrina Sbaraini; Samanta Inês Vanzin; Maria Inês Soares Melecchi; Elina Bastos Caramão; Ionara Rodrigues Siqueira
Journal:  BMC Complement Altern Med       Date:  2012-04-12       Impact factor: 3.659

6.  Antidepressant-like effect of novel 5-HT3 receptor antagonist N-n-butyl-3-ethoxyquinoxalin-2-carboxamide (6p): an approach using rodent behavioral antidepressant tests.

Authors:  Shvetank Bhatt; Radhakrishnan Mahesh; Thangaraj Devadoss; Ankur Kumar Jindal
Journal:  Indian J Pharmacol       Date:  2013 Jul-Aug       Impact factor: 1.200

7.  Antidepressant activity of methanolic extract of amaranthus spinosus.

Authors:  B S Ashok Kumar; K Lakshman; C Velmurugan; S M Sridhar; Saran Gopisetty
Journal:  Basic Clin Neurosci       Date:  2014

8.  Antidepressant Potential of 5-HT3 Receptor Antagonist, N-n- propyl-3-ethoxyquinoxaline-2-carboxamide (6n).

Authors:  R Mahesh; S Bhatt; T Devadoss; Ak Jindal; Bk Gautam; Dk Pandey
Journal:  J Young Pharm       Date:  2012-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.